在患有尾腺癌的患者中,血清瘤标记物和结果
Abdelrahman Yousef1, Mahmoud Yousef1, Mohammad A Zeineddine1
1Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
JAMA network open
|February 28, 2024
概括
血清瘤标志物升高,包括癌胚抗原 (CEA),碳水化合物抗原19-9 (CA19-9),癌症抗原125 (CA125),与尾腺癌患者的生存率降低有关. 这些标记物应该是初始诊断工作的一部分.
科学领域:
- 在瘤学瘤学.
- 生物标志物研究 生物标志物研究
- 癌症的诊断 癌症的诊断
背景情况:
- 像CEA,CA19-9和CA125这样的血清瘤标志物已在治疗肠道和妇科癌症方面得到证实.
- 关于它们在尾腺癌中的有用性存在有限的数据.
研究的目的:
- 评估血清瘤标志物 (CEA,CA19-9,CA125) 与尾腺癌的临床结果之间的关联.
- 探索与病理和分子特征的相关性.
主要方法:
- 对1338名尾腺癌患者进行了回顾性队列研究.
- 对血清瘤标志物水平 (CEA,CA19-9,CA125) 和整体存活率的分析.
- 康克斯比例危险回归用于生存分析.
主要成果:
- 较高的CEA,CA19-9或CA125个别与明显更差的5年生存率有关.
- 更高的标志物水平,特别是在前10个百分点中,与明显减少的生存率相关.
- 随着越来越多的标志物升高,死亡风险逐渐增加,所有三种升高的标志物都显示出11倍的风险增加.
结论:
- 血清CEA,CA19-9和CA125与尾腺癌的整体存活率显著相关.
- 这些生物标志物应纳入诊断患者的初始诊断评估.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
792
相关概念视频
01:29Appendicitis-II: Diagnostic Studies and Management
80
Diagnosing and managing appendicitis requires a structured and comprehensive approach that spans from initial assessment to postoperative care. Here is an overview of the process:
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
Diagnosing Appendicitis
It requires a multifaceted approach, starting with a detailed physical examination to pinpoint the location and nature of the pain and identify any associated symptoms. Laboratory tests play a crucial role. A complete Blood Count (CBC) typically reveals leukocytosis (an increased number of...
80
01:21Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345